Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

US$M US$M

_______ _________ _________

Continuing operations:

Revenue 2,436.3 1,796.5

Cost of sales (312.7) (252.9)

__________ __________

Gross profit 2,123.6 1,543.6

Research and development (including other

intangible asset impairments of US$256.4

million (2006: US$nil)) (775.2) (295.8)

Selling, general and administrative

(including goodwill and other intangible

asset impairments of US$134.1 million (2006: (1,381.1) (1,219.9)

US$273.0 million)

Gain on sale of product rights 102.9 63.0

__________ __________

Operating profit 70.2 90.9

Investment revenues 50.6 50.5

Finance costs (93.1) (27.0)

Other income/(expense), net 1.9 9.4

Share of post tax profit from associates and

joint ventures 1.8 5.8

__________ __________

Profit before taxation 31.4 129.6

Taxation 4 51.0 (114.0)

__________ __________

Profit for the year from continuing

Operations 82.4 15.6

Discontinued operations:

Gain on disposal of discontinued operation,

net of tax
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Synedgen Inc. is pleased to announce ... Manager. , Dr. Nguyen brings to Synedgen critical regulatory ... company as it moves forward in the FDA regulatory ... two years. Dr. Nguyen will lead the management of ... documents that must be completed in order to initiate ...
(Date:5/4/2015)... 4, 2015 Tobira Therapeutics, Inc. (NASDAQ: ... development and commercialization of novel treatments for liver ... its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, ... of the merger, Tobira raised $40 million of ... and all current Tobira institutional investors, including the ...
(Date:5/4/2015)... 2015 GliaCure, a privately-held biotechnology company ... neurological and neuropsychiatric disorders based on glial targets, ... patients in a Phase 1b clinical trial of ... as a potential disease-modifying treatment. GliaCure,s innovative approach ... it both promotes the clearance of amyloid and ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... pleased to announce the appointment of Dr. Roger ... extensive experience guiding biotech companies in matters including ... Fluorinov,s leadership team and adds significant regulatory expertise ... Dr. Garceau brings 30 years of pharmaceutical ...
Breaking Biology Technology:Synedgen Announces the Appointment of Regulatory Affairs Manager 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... electrical properties, carbon nanotubes are attractive building ... sensors, logic devices, and memory elements. ... arrays of individual carbon nanotubes and the ... large-scale commercial use. Now, researchers at ...
... 7, 2010 Naurex Inc., a clinical-stage company developing ... neurology, reported that data being presented today at the ... (ACNP) further confirm that its lead antidepressant candidate GLYX-13 ... that have limited the clinical utility of other NMDA ...
... completely, it would be more than six feet long. It,s hard ... your cells, but that,s exactly how it works. For ... DNA is packaged in cells, and have found strong indications that the ... mostly of an amino acid molecule called a histone influences the ...
Cached Biology Technology:Using new materials to make more reliable nanoelectromechanical systems 2New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine 2New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine 3New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine 4UNC-led team tests commonly used antibodies 2
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... release is available in Spanish . , ... processes, but also those that do not. This is why ... healthy cells. With this aim in mind, a team from ... of the C1P molecule. Today two types of ...
... N.Y. New tires allow race cars to take tight ... similar advantages: They are not necessary for basic flight but ... "To escape a predator, you don,t have to be fast, ... a world authority on animal behavior, ecology and evolution and ...
... pollution has already spurred public health officials to advise eating ... in a warmer world. So suggests a paper that ... . Sue Natali, a postdoctoral associate in botany at ... mercury levels in soils under trees growing in air enriched ...
Cached Biology News:The quest for specific anti-inflammatory treatment 2The quest for specific anti-inflammatory treatment 3Hind wings help butterflies make swift turns to evade predators, study finds 2To climate-change worries, add 1 more: Extended mercury threat 2To climate-change worries, add 1 more: Extended mercury threat 3
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
...
... to Sf-900 II SFM.Sf21 ... from Spodoptera frugiperda (Fall ... (1). The Sf21 cells ... suspension culture in Sf-900 ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Biology Products: